Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.
According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “
Several other research firms also recently issued reports on ASND. Wedbush started coverage on shares of Ascendis Pharma A/S in a research report on Monday, September 26th. They issued an “outperform” rating and a $34.00 price target for the company. Leerink Swann reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a report on Friday, September 2nd. Finally, TheStreet raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Tuesday, September 6th.
Shares of Ascendis Pharma A/S (NASDAQ:ASND) traded down 0.61% during trading on Monday, hitting $20.51. 58,181 shares of the stock traded hands. The stock has a 50 day moving average price of $0.00 and a 200-day moving average price of $0.00. Ascendis Pharma A/S has a 1-year low of $11.92 and a 1-year high of $21.79.
Institutional investors have recently bought and sold shares of the company. Janus Capital Management bought a new position in shares of Ascendis Pharma A/S during the third quarter worth $12,651,000. Baker BROS. Advisors LP bought a new position in shares of Ascendis Pharma A/S during the third quarter worth $14,985,000. RA Capital Management LLC increased its position in shares of Ascendis Pharma A/S by 7.9% in the third quarter. RA Capital Management LLC now owns 3,681,491 shares of the company’s stock worth $73,998,000 after buying an additional 268,634 shares during the period. Finally, Sphera Funds Management LTD. increased its position in shares of Ascendis Pharma A/S by 0.6% in the third quarter. Sphera Funds Management LTD. now owns 263,500 shares of the company’s stock worth $5,296,000 after buying an additional 1,700 shares during the period. 44.40% of the stock is currently owned by hedge funds and other institutional investors.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.